Skip to main content

Table 2 Adverse events

From: Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme

Adverse events (patients receiving ≥ 1 dose of trifluridine/tipiracil)

n

% (n = 194)

≥1 AE

106

55%

Deranged renal/creatinine

4

2%

Anaemia

12

6%

Neutropenia

59

30%

Neutropenic sepsis

8

4%

Thrombocytopenia

8

4%

Pancytopenia

2

1%

Leukopenia

10

5%

Lymphocytopenia/lymphopenia

2

1%

Hyperbilirubinaemia

3

2%

Other

71

37%